Ireland
--:--IST
Starting soon Phase 3

Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants

NCT06810154 · tracked via the Priya Life Science Canada tracker
Phase
Phase 3
Started
2025-06-01
Last updated
2025-02-05

Condition(s) studied

Necrotizing Enterocolitis (NEC)

Investigational drug(s) / intervention(s)

Multi-strain probiotics

Multi-strain probiotics: Infants will be started on probiotics (Bifidobacterium and Lacticaseibacillus) with enetral feed.

Study summary

The goal of this clinical trial is to evaluate whether multi-strain probiotics of lactobacillus and bifidobacterium can prevent necrotizing enterocolitis (NEC) in preterm infants born at less than 32 weeks of gestation. The main questions it aims to answer are:

* Does the use of a multi-strain probiotic combination reduce the incidence of NEC in preterm infants?
* Are there any adverse effects associated with the administration of this probiotic combination?

Eligibility

Sex
ALL
Min age
0 Hours
Max age
72 Hours
Healthy volunteers
No
Inclusion Criteria: * Infants born between \<32 0/7 weeks gestation. Exclusion Criteria: * Major congenital or chromosomal abnormalities * Conditions affecting gastrointestinal systems that prohibit infants from starting on feed in the first 72 hours after birth.

Primary outcome measure(s)

  • Incidence of necrotizing enterocolitis (NEC — From date of randomization until the date of 34 weeks corrected gestational age or or date of death from any cause, whichever came first
    NEC defined in CNN according to modified Bell's criteria.

Trial sites (4)

FacilityCityRegionStatus
Foothills Medical Center Calgary Alberta
Royal Alexandra Hospital Edmonton Alberta
Children's and Women's health of Britch Columbia Vancouver British Columbia
IWK Halifax Canada
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06810154 on ClinicalTrials.gov ↗ ← All trials in Canada